nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolvaptan—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0595	0.0906	CbGbCtD
Tolvaptan—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0539	0.082	CbGbCtD
Tolvaptan—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0465	0.0708	CbGbCtD
Tolvaptan—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0451	0.0687	CbGbCtD
Tolvaptan—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0408	0.0621	CbGbCtD
Tolvaptan—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0408	0.0621	CbGbCtD
Tolvaptan—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.0391	0.0596	CbGbCtD
Tolvaptan—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0379	0.0578	CbGbCtD
Tolvaptan—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0357	0.0543	CbGbCtD
Tolvaptan—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0357	0.0543	CbGbCtD
Tolvaptan—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0323	0.0491	CbGbCtD
Tolvaptan—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0323	0.0491	CbGbCtD
Tolvaptan—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.0303	0.0461	CbGbCtD
Tolvaptan—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0279	0.0424	CbGbCtD
Tolvaptan—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.027	0.0412	CbGbCtD
Tolvaptan—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0245	0.0372	CbGbCtD
Tolvaptan—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0245	0.0372	CbGbCtD
Tolvaptan—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0234	0.0357	CbGbCtD
Tolvaptan—AVPR1A—lung—acquired immunodeficiency syndrome	0.0031	0.127	CbGeAlD
Tolvaptan—AVPR1A—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00304	0.0417	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00302	0.0414	CbGpPWpGaD
Tolvaptan—AVPR1A—central nervous system—acquired immunodeficiency syndrome	0.00277	0.114	CbGeAlD
Tolvaptan—AVPR2—lung—acquired immunodeficiency syndrome	0.00257	0.106	CbGeAlD
Tolvaptan—AVPR2—nervous system—acquired immunodeficiency syndrome	0.00238	0.0977	CbGeAlD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00236	0.0324	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00234	0.0321	CbGpPWpGaD
Tolvaptan—AVPR2—central nervous system—acquired immunodeficiency syndrome	0.00229	0.0941	CbGeAlD
Tolvaptan—AVPR1A—brain—acquired immunodeficiency syndrome	0.0022	0.0901	CbGeAlD
Tolvaptan—AVPR2—brain—acquired immunodeficiency syndrome	0.00182	0.0747	CbGeAlD
Tolvaptan—AVPR1A—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.0017	0.0233	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00168	0.0231	CbGpPWpGaD
Tolvaptan—AVPR1A—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.0016	0.0219	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00158	0.0217	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00158	0.0217	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00157	0.0215	CbGpPWpGaD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.00143	0.0196	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.00142	0.0195	CbGpPWpGaD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00129	0.0177	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00128	0.0176	CbGpPWpGaD
Tolvaptan—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.00122	0.05	CbGeAlD
Tolvaptan—AVPR1A—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.0012	0.0165	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.0012	0.0164	CbGpPWpGaD
Tolvaptan—AVPR1A—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00109	0.015	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00109	0.0149	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000958	0.0131	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000951	0.0131	CbGpPWpGaD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000882	0.0121	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000876	0.012	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000866	0.0119	CbGpPWpGaD
Tolvaptan—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000863	0.0354	CbGeAlD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00086	0.0118	CbGpPWpGaD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000798	0.011	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000792	0.0109	CbGpPWpGaD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00075	0.0103	CbGpPWpGaD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00075	0.0103	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000745	0.0102	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000745	0.0102	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00073	0.01	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000724	0.00994	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00066	0.00906	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000655	0.00899	CbGpPWpGaD
Tolvaptan—Vismodegib—ALB—acquired immunodeficiency syndrome	0.000631	1	CrCbGaD
Tolvaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000625	0.00857	CbGpPWpGaD
Tolvaptan—AVPR2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00062	0.00851	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000618	0.00848	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000614	0.00842	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000592	0.00812	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000588	0.00806	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000587	0.00806	CbGpPWpGaD
Tolvaptan—AVPR2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000583	0.008	CbGpPWpGaD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000571	0.00783	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000567	0.00778	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000535	0.00735	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000531	0.00729	CbGpPWpGaD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000514	0.00706	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000511	0.00701	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000503	0.00691	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000503	0.00691	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.0005	0.00686	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.0005	0.00686	CbGpPWpGaD
Tolvaptan—Immune system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000475	0.00194	CcSEcCtD
Tolvaptan—Dysgeusia—Indinavir—acquired immunodeficiency syndrome	0.000475	0.00194	CcSEcCtD
Tolvaptan—Mediastinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000474	0.00193	CcSEcCtD
Tolvaptan—Nervous system disorder—Abacavir—acquired immunodeficiency syndrome	0.000473	0.00193	CcSEcCtD
Tolvaptan—ABCB1—retina—acquired immunodeficiency syndrome	0.000473	0.0194	CbGeAlD
Tolvaptan—Malaise—Zidovudine—acquired immunodeficiency syndrome	0.00047	0.00192	CcSEcCtD
Tolvaptan—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000469	0.0192	CbGeAlD
Tolvaptan—Skin disorder—Abacavir—acquired immunodeficiency syndrome	0.000469	0.00191	CcSEcCtD
Tolvaptan—Renal failure—Lamivudine—acquired immunodeficiency syndrome	0.000468	0.00191	CcSEcCtD
Tolvaptan—Anorexia—Nelfinavir—acquired immunodeficiency syndrome	0.000468	0.00191	CcSEcCtD
Tolvaptan—Syncope—Zidovudine—acquired immunodeficiency syndrome	0.000468	0.00191	CcSEcCtD
Tolvaptan—Anorexia—Stavudine—acquired immunodeficiency syndrome	0.000467	0.0019	CcSEcCtD
Tolvaptan—Urinary tract disorder—Ritonavir—acquired immunodeficiency syndrome	0.00046	0.00188	CcSEcCtD
Tolvaptan—Anorexia—Abacavir—acquired immunodeficiency syndrome	0.00046	0.00187	CcSEcCtD
Tolvaptan—Loss of consciousness—Zidovudine—acquired immunodeficiency syndrome	0.000458	0.00187	CcSEcCtD
Tolvaptan—Malnutrition—Efavirenz—acquired immunodeficiency syndrome	0.000458	0.00187	CcSEcCtD
Tolvaptan—Connective tissue disorder—Ritonavir—acquired immunodeficiency syndrome	0.000458	0.00187	CcSEcCtD
Tolvaptan—Urethral disorder—Ritonavir—acquired immunodeficiency syndrome	0.000457	0.00186	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000451	0.00619	CbGpPWpGaD
Tolvaptan—Ill-defined disorder—Indinavir—acquired immunodeficiency syndrome	0.00045	0.00183	CcSEcCtD
Tolvaptan—Dysgeusia—Efavirenz—acquired immunodeficiency syndrome	0.000449	0.00183	CcSEcCtD
Tolvaptan—AVPR2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000447	0.00614	CbGpPWpGaD
Tolvaptan—CYP3A4—blood—acquired immunodeficiency syndrome	0.000447	0.0183	CbGeAlD
Tolvaptan—Body temperature increased—Didanosine—acquired immunodeficiency syndrome	0.000446	0.00182	CcSEcCtD
Tolvaptan—Asthenia—Amprenavir—acquired immunodeficiency syndrome	0.000444	0.00181	CcSEcCtD
Tolvaptan—Urinary tract disorder—Saquinavir—acquired immunodeficiency syndrome	0.000443	0.00181	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Zidovudine—acquired immunodeficiency syndrome	0.000441	0.0018	CcSEcCtD
Tolvaptan—Decreased appetite—Nevirapine—acquired immunodeficiency syndrome	0.000441	0.0018	CcSEcCtD
Tolvaptan—Connective tissue disorder—Saquinavir—acquired immunodeficiency syndrome	0.000441	0.0018	CcSEcCtD
Tolvaptan—Urethral disorder—Saquinavir—acquired immunodeficiency syndrome	0.000439	0.00179	CcSEcCtD
Tolvaptan—Discomfort—Zidovudine—acquired immunodeficiency syndrome	0.000439	0.00179	CcSEcCtD
Tolvaptan—Malnutrition—Delavirdine—acquired immunodeficiency syndrome	0.000438	0.00179	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Nevirapine—acquired immunodeficiency syndrome	0.000438	0.00179	CcSEcCtD
Tolvaptan—Pruritus—Amprenavir—acquired immunodeficiency syndrome	0.000438	0.00178	CcSEcCtD
Tolvaptan—Malaise—Indinavir—acquired immunodeficiency syndrome	0.000437	0.00178	CcSEcCtD
Tolvaptan—Syncope—Indinavir—acquired immunodeficiency syndrome	0.000435	0.00177	CcSEcCtD
Tolvaptan—Cardiac disorder—Ritonavir—acquired immunodeficiency syndrome	0.000432	0.00176	CcSEcCtD
Tolvaptan—Dysgeusia—Delavirdine—acquired immunodeficiency syndrome	0.000429	0.00175	CcSEcCtD
Tolvaptan—Decreased appetite—Nelfinavir—acquired immunodeficiency syndrome	0.000427	0.00174	CcSEcCtD
Tolvaptan—Loss of consciousness—Indinavir—acquired immunodeficiency syndrome	0.000426	0.00174	CcSEcCtD
Tolvaptan—Decreased appetite—Stavudine—acquired immunodeficiency syndrome	0.000426	0.00174	CcSEcCtD
Tolvaptan—Anaphylactic shock—Zidovudine—acquired immunodeficiency syndrome	0.000426	0.00174	CcSEcCtD
Tolvaptan—Ill-defined disorder—Efavirenz—acquired immunodeficiency syndrome	0.000425	0.00173	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000424	0.00173	CcSEcCtD
Tolvaptan—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.000423	0.00173	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.000423	0.00172	CcSEcCtD
Tolvaptan—Angiopathy—Ritonavir—acquired immunodeficiency syndrome	0.000423	0.00172	CcSEcCtD
Tolvaptan—Immune system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000421	0.00172	CcSEcCtD
Tolvaptan—Connective tissue disorder—Lamivudine—acquired immunodeficiency syndrome	0.00042	0.00171	CcSEcCtD
Tolvaptan—Mediastinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.00042	0.00171	CcSEcCtD
Tolvaptan—Decreased appetite—Abacavir—acquired immunodeficiency syndrome	0.000419	0.00171	CcSEcCtD
Tolvaptan—Constipation—Stavudine—acquired immunodeficiency syndrome	0.000419	0.00171	CcSEcCtD
Tolvaptan—Shock—Zidovudine—acquired immunodeficiency syndrome	0.000419	0.00171	CcSEcCtD
Tolvaptan—Feeling abnormal—Nevirapine—acquired immunodeficiency syndrome	0.000418	0.0017	CcSEcCtD
Tolvaptan—Nervous system disorder—Zidovudine—acquired immunodeficiency syndrome	0.000417	0.0017	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.000416	0.0017	CcSEcCtD
Tolvaptan—Cardiac disorder—Saquinavir—acquired immunodeficiency syndrome	0.000416	0.0017	CcSEcCtD
Tolvaptan—Hypersensitivity—Didanosine—acquired immunodeficiency syndrome	0.000416	0.00169	CcSEcCtD
Tolvaptan—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.000413	0.00169	CcSEcCtD
Tolvaptan—Malaise—Efavirenz—acquired immunodeficiency syndrome	0.000413	0.00168	CcSEcCtD
Tolvaptan—Syncope—Efavirenz—acquired immunodeficiency syndrome	0.000411	0.00168	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Indinavir—acquired immunodeficiency syndrome	0.00041	0.00167	CcSEcCtD
Tolvaptan—Discomfort—Indinavir—acquired immunodeficiency syndrome	0.000408	0.00166	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000408	0.00559	CbGpPWpGaD
Tolvaptan—Ill-defined disorder—Delavirdine—acquired immunodeficiency syndrome	0.000407	0.00166	CcSEcCtD
Tolvaptan—Angiopathy—Saquinavir—acquired immunodeficiency syndrome	0.000407	0.00166	CcSEcCtD
Tolvaptan—Anorexia—Zidovudine—acquired immunodeficiency syndrome	0.000406	0.00165	CcSEcCtD
Tolvaptan—Malnutrition—Ritonavir—acquired immunodeficiency syndrome	0.000405	0.00165	CcSEcCtD
Tolvaptan—Immune system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000405	0.00165	CcSEcCtD
Tolvaptan—Feeling abnormal—Nelfinavir—acquired immunodeficiency syndrome	0.000405	0.00165	CcSEcCtD
Tolvaptan—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.000405	0.00165	CcSEcCtD
Tolvaptan—AVPR2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000405	0.00555	CbGpPWpGaD
Tolvaptan—Mediastinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000404	0.00165	CcSEcCtD
Tolvaptan—Dry mouth—Indinavir—acquired immunodeficiency syndrome	0.000404	0.00165	CcSEcCtD
Tolvaptan—Loss of consciousness—Efavirenz—acquired immunodeficiency syndrome	0.000403	0.00164	CcSEcCtD
Tolvaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000403	0.00553	CbGpPWpGaD
Tolvaptan—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.000401	0.00163	CcSEcCtD
Tolvaptan—AVPR2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.0004	0.00549	CbGpPWpGaD
Tolvaptan—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.000399	0.00163	CcSEcCtD
Tolvaptan—Feeling abnormal—Abacavir—acquired immunodeficiency syndrome	0.000398	0.00162	CcSEcCtD
Tolvaptan—Dysgeusia—Ritonavir—acquired immunodeficiency syndrome	0.000397	0.00162	CcSEcCtD
Tolvaptan—Anaphylactic shock—Indinavir—acquired immunodeficiency syndrome	0.000396	0.00161	CcSEcCtD
Tolvaptan—Malaise—Delavirdine—acquired immunodeficiency syndrome	0.000395	0.00161	CcSEcCtD
Tolvaptan—Syncope—Delavirdine—acquired immunodeficiency syndrome	0.000393	0.0016	CcSEcCtD
Tolvaptan—Malnutrition—Saquinavir—acquired immunodeficiency syndrome	0.00039	0.00159	CcSEcCtD
Tolvaptan—Shock—Indinavir—acquired immunodeficiency syndrome	0.000389	0.00159	CcSEcCtD
Tolvaptan—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.000388	0.00158	CcSEcCtD
Tolvaptan—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.000388	0.00158	CcSEcCtD
Tolvaptan—Headache—Amprenavir—acquired immunodeficiency syndrome	0.000388	0.00158	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.000387	0.00158	CcSEcCtD
Tolvaptan—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.000387	0.00158	CcSEcCtD
Tolvaptan—Immune system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000386	0.00158	CcSEcCtD
Tolvaptan—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.000386	0.00157	CcSEcCtD
Tolvaptan—Discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000385	0.00157	CcSEcCtD
Tolvaptan—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000385	0.00157	CcSEcCtD
Tolvaptan—Loss of consciousness—Delavirdine—acquired immunodeficiency syndrome	0.000385	0.00157	CcSEcCtD
Tolvaptan—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.000384	0.00157	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000383	0.00526	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000383	0.00526	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000383	0.00525	CbGpPWpGaD
Tolvaptan—Dysgeusia—Saquinavir—acquired immunodeficiency syndrome	0.000382	0.00156	CcSEcCtD
Tolvaptan—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.000382	0.00156	CcSEcCtD
Tolvaptan—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000381	0.00155	CcSEcCtD
Tolvaptan—AVPR2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00038	0.00522	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00038	0.00522	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00038	0.00522	CbGpPWpGaD
Tolvaptan—Anorexia—Indinavir—acquired immunodeficiency syndrome	0.000377	0.00154	CcSEcCtD
Tolvaptan—Ill-defined disorder—Ritonavir—acquired immunodeficiency syndrome	0.000376	0.00153	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000374	0.00514	CbGpPWpGaD
Tolvaptan—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.000374	0.00152	CcSEcCtD
Tolvaptan—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.000372	0.00152	CcSEcCtD
Tolvaptan—AVPR2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000372	0.0051	CbGpPWpGaD
Tolvaptan—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.00037	0.00151	CcSEcCtD
Tolvaptan—Discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000369	0.0015	CcSEcCtD
Tolvaptan—Shock—Efavirenz—acquired immunodeficiency syndrome	0.000368	0.0015	CcSEcCtD
Tolvaptan—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000368	0.0015	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000367	0.0015	CcSEcCtD
Tolvaptan—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000367	0.0015	CcSEcCtD
Tolvaptan—Malaise—Ritonavir—acquired immunodeficiency syndrome	0.000366	0.00149	CcSEcCtD
Tolvaptan—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000365	0.00149	CcSEcCtD
Tolvaptan—AVPR1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000365	0.00501	CbGpPWpGaD
Tolvaptan—Dysgeusia—Lamivudine—acquired immunodeficiency syndrome	0.000365	0.00149	CcSEcCtD
Tolvaptan—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000364	0.00148	CcSEcCtD
Tolvaptan—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000364	0.00148	CcSEcCtD
Tolvaptan—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.000364	0.00148	CcSEcCtD
Tolvaptan—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000363	0.00148	CcSEcCtD
Tolvaptan—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000363	0.0149	CbGeAlD
Tolvaptan—AVPR2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000362	0.00497	CbGpPWpGaD
Tolvaptan—Ill-defined disorder—Saquinavir—acquired immunodeficiency syndrome	0.000362	0.00148	CcSEcCtD
Tolvaptan—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000362	0.00148	CcSEcCtD
Tolvaptan—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000361	0.00147	CcSEcCtD
Tolvaptan—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000359	0.00146	CcSEcCtD
Tolvaptan—Anorexia—Efavirenz—acquired immunodeficiency syndrome	0.000357	0.00145	CcSEcCtD
Tolvaptan—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.000356	0.00145	CcSEcCtD
Tolvaptan—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000355	0.00145	CcSEcCtD
Tolvaptan—Headache—Didanosine—acquired immunodeficiency syndrome	0.000353	0.00144	CcSEcCtD
Tolvaptan—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000352	0.00144	CcSEcCtD
Tolvaptan—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000352	0.00144	CcSEcCtD
Tolvaptan—Malaise—Saquinavir—acquired immunodeficiency syndrome	0.000352	0.00143	CcSEcCtD
Tolvaptan—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000351	0.00143	CcSEcCtD
Tolvaptan—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000351	0.00143	CcSEcCtD
Tolvaptan—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.00035	0.00143	CcSEcCtD
Tolvaptan—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000349	0.0143	CbGeAlD
Tolvaptan—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000348	0.00142	CcSEcCtD
Tolvaptan—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000348	0.00142	CcSEcCtD
Tolvaptan—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000347	0.00141	CcSEcCtD
Tolvaptan—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000346	0.00141	CcSEcCtD
Tolvaptan—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000346	0.00141	CcSEcCtD
Tolvaptan—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	0.000345	0.00141	CcSEcCtD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000345	0.00473	CbGpPWpGaD
Tolvaptan—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000344	0.0014	CcSEcCtD
Tolvaptan—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000343	0.0014	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000343	0.0014	CcSEcCtD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000342	0.0047	CbGpPWpGaD
Tolvaptan—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000342	0.00139	CcSEcCtD
Tolvaptan—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000341	0.00139	CcSEcCtD
Tolvaptan—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000341	0.00139	CcSEcCtD
Tolvaptan—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000341	0.00139	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000339	0.00465	CbGpPWpGaD
Tolvaptan—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000339	0.00138	CcSEcCtD
Tolvaptan—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000338	0.00138	CcSEcCtD
Tolvaptan—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000336	0.00137	CcSEcCtD
Tolvaptan—AVPR2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000336	0.00461	CbGpPWpGaD
Tolvaptan—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000336	0.00137	CcSEcCtD
Tolvaptan—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000336	0.0138	CbGeAlD
Tolvaptan—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.000336	0.00137	CcSEcCtD
Tolvaptan—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000335	0.00137	CcSEcCtD
Tolvaptan—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000335	0.00137	CcSEcCtD
Tolvaptan—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000334	0.00136	CcSEcCtD
Tolvaptan—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000332	0.0136	CbGeAlD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—CXCL12—acquired immunodeficiency syndrome	0.000331	0.00454	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—CXCR4—acquired immunodeficiency syndrome	0.000331	0.00454	CbGpPWpGaD
Tolvaptan—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.00033	0.00135	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.00033	0.00135	CcSEcCtD
Tolvaptan—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000328	0.00134	CcSEcCtD
Tolvaptan—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000327	0.00133	CcSEcCtD
Tolvaptan—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000326	0.00133	CcSEcCtD
Tolvaptan—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000326	0.00133	CcSEcCtD
Tolvaptan—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000325	0.00133	CcSEcCtD
Tolvaptan—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000325	0.00132	CcSEcCtD
Tolvaptan—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000325	0.00132	CcSEcCtD
Tolvaptan—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000325	0.00132	CcSEcCtD
Tolvaptan—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000324	0.00132	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000323	0.00132	CcSEcCtD
Tolvaptan—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000321	0.00131	CcSEcCtD
Tolvaptan—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.00032	0.0013	CcSEcCtD
Tolvaptan—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000319	0.0013	CcSEcCtD
Tolvaptan—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000318	0.0013	CcSEcCtD
Tolvaptan—ABCB1—blood—acquired immunodeficiency syndrome	0.000316	0.013	CbGeAlD
Tolvaptan—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000315	0.00129	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000315	0.00128	CcSEcCtD
Tolvaptan—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000313	0.00128	CcSEcCtD
Tolvaptan—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000313	0.00128	CcSEcCtD
Tolvaptan—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000313	0.00128	CcSEcCtD
Tolvaptan—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000312	0.00127	CcSEcCtD
Tolvaptan—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000311	0.00127	CcSEcCtD
Tolvaptan—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.00031	0.00126	CcSEcCtD
Tolvaptan—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000309	0.00126	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000309	0.00126	CcSEcCtD
Tolvaptan—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000308	0.00126	CcSEcCtD
Tolvaptan—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000308	0.00125	CcSEcCtD
Tolvaptan—Headache—Stavudine—acquired immunodeficiency syndrome	0.000307	0.00125	CcSEcCtD
Tolvaptan—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000306	0.00125	CcSEcCtD
Tolvaptan—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000306	0.0126	CbGeAlD
Tolvaptan—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000305	0.00125	CcSEcCtD
Tolvaptan—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000305	0.0125	CbGeAlD
Tolvaptan—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000304	0.00124	CcSEcCtD
Tolvaptan—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000304	0.00124	CcSEcCtD
Tolvaptan—Headache—Abacavir—acquired immunodeficiency syndrome	0.000302	0.00123	CcSEcCtD
Tolvaptan—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000301	0.00123	CcSEcCtD
Tolvaptan—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000301	0.00123	CcSEcCtD
Tolvaptan—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000299	0.00122	CcSEcCtD
Tolvaptan—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000298	0.00121	CcSEcCtD
Tolvaptan—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000296	0.00121	CcSEcCtD
Tolvaptan—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000295	0.0012	CcSEcCtD
Tolvaptan—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000295	0.0012	CcSEcCtD
Tolvaptan—ABCB1—vagina—acquired immunodeficiency syndrome	0.000293	0.012	CbGeAlD
Tolvaptan—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000292	0.00119	CcSEcCtD
Tolvaptan—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000292	0.00119	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000292	0.004	CbGpPWpGaD
Tolvaptan—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000291	0.00119	CcSEcCtD
Tolvaptan—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000291	0.00119	CcSEcCtD
Tolvaptan—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.00029	0.00118	CcSEcCtD
Tolvaptan—AVPR2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000289	0.00397	CbGpPWpGaD
Tolvaptan—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000288	0.00117	CcSEcCtD
Tolvaptan—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000287	0.00117	CcSEcCtD
Tolvaptan—ABCB1—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	0.000286	0.00393	CbGpPWpGaD
Tolvaptan—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000286	0.00116	CcSEcCtD
Tolvaptan—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000284	0.00116	CcSEcCtD
Tolvaptan—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000283	0.00115	CcSEcCtD
Tolvaptan—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000283	0.00115	CcSEcCtD
Tolvaptan—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000281	0.00115	CcSEcCtD
Tolvaptan—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.00028	0.00114	CcSEcCtD
Tolvaptan—ABCB1—lung—acquired immunodeficiency syndrome	0.000277	0.0114	CbGeAlD
Tolvaptan—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000277	0.00113	CcSEcCtD
Tolvaptan—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000276	0.00112	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000275	0.00112	CcSEcCtD
Tolvaptan—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000273	0.00111	CcSEcCtD
Tolvaptan—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000272	0.00111	CcSEcCtD
Tolvaptan—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000271	0.0011	CcSEcCtD
Tolvaptan—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000268	0.00109	CcSEcCtD
Tolvaptan—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000267	0.00109	CcSEcCtD
Tolvaptan—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000265	0.00108	CcSEcCtD
Tolvaptan—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000264	0.00108	CcSEcCtD
Tolvaptan—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000264	0.00107	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000263	0.0036	CbGpPWpGaD
Tolvaptan—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000262	0.00107	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000262	0.00107	CcSEcCtD
Tolvaptan—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000262	0.00107	CcSEcCtD
Tolvaptan—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000262	0.00107	CcSEcCtD
Tolvaptan—AVPR2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000261	0.00358	CbGpPWpGaD
Tolvaptan—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.00026	0.00106	CcSEcCtD
Tolvaptan—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000257	0.00105	CcSEcCtD
Tolvaptan—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000257	0.0105	CbGeAlD
Tolvaptan—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000256	0.00104	CcSEcCtD
Tolvaptan—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000253	0.00103	CcSEcCtD
Tolvaptan—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000253	0.00103	CcSEcCtD
Tolvaptan—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000252	0.00103	CcSEcCtD
Tolvaptan—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.00025	0.00102	CcSEcCtD
Tolvaptan—Headache—Indinavir—acquired immunodeficiency syndrome	0.000248	0.00101	CcSEcCtD
Tolvaptan—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000247	0.00101	CcSEcCtD
Tolvaptan—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000247	0.0101	CbGeAlD
Tolvaptan—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000245	0.000998	CcSEcCtD
Tolvaptan—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000244	0.000994	CcSEcCtD
Tolvaptan—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.00024	0.000979	CcSEcCtD
Tolvaptan—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000237	0.000968	CcSEcCtD
Tolvaptan—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000237	0.000965	CcSEcCtD
Tolvaptan—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000235	0.000959	CcSEcCtD
Tolvaptan—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000235	0.000957	CcSEcCtD
Tolvaptan—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000234	0.000955	CcSEcCtD
Tolvaptan—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000234	0.000955	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000231	0.00317	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.00023	0.00316	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.00023	0.00315	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000229	0.00314	CbGpPWpGaD
Tolvaptan—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000229	0.000932	CcSEcCtD
Tolvaptan—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000226	0.000923	CcSEcCtD
Tolvaptan—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000225	0.000919	CcSEcCtD
Tolvaptan—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000224	0.000914	CcSEcCtD
Tolvaptan—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000224	0.000913	CcSEcCtD
Tolvaptan—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000222	0.000906	CcSEcCtD
Tolvaptan—AVPR1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000221	0.00304	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000221	0.00304	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.00022	0.00301	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.00022	0.00301	CbGpPWpGaD
Tolvaptan—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000219	0.000892	CcSEcCtD
Tolvaptan—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000218	0.000889	CcSEcCtD
Tolvaptan—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000218	0.000889	CcSEcCtD
Tolvaptan—ABCB1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	0.000217	0.00298	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	0.000217	0.00298	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000217	0.00297	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000217	0.00297	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000215	0.00295	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000215	0.00295	CbGpPWpGaD
Tolvaptan—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000215	0.000877	CcSEcCtD
Tolvaptan—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000213	0.000867	CcSEcCtD
Tolvaptan—ABCB1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	0.000211	0.0029	CbGpPWpGaD
Tolvaptan—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000211	0.000859	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000209	0.00287	CbGpPWpGaD
Tolvaptan—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000208	0.000848	CcSEcCtD
Tolvaptan—AVPR2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000208	0.00285	CbGpPWpGaD
Tolvaptan—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000207	0.000845	CcSEcCtD
Tolvaptan—ABCB1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	0.000206	0.00283	CbGpPWpGaD
Tolvaptan—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000201	0.000819	CcSEcCtD
Tolvaptan—AVPR1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.0002	0.00275	CbGpPWpGaD
Tolvaptan—Headache—Saquinavir—acquired immunodeficiency syndrome	0.0002	0.000814	CcSEcCtD
Tolvaptan—AVPR2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000199	0.00273	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000197	0.0027	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000197	0.0027	CbGpPWpGaD
Tolvaptan—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000197	0.000801	CcSEcCtD
Tolvaptan—ABCB1—brain—acquired immunodeficiency syndrome	0.000196	0.00805	CbGeAlD
Tolvaptan—AVPR2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000195	0.00268	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000195	0.00268	CbGpPWpGaD
Tolvaptan—Headache—Lamivudine—acquired immunodeficiency syndrome	0.00019	0.000776	CcSEcCtD
Tolvaptan—ABCB1—lymph node—acquired immunodeficiency syndrome	0.00019	0.00778	CbGeAlD
Tolvaptan—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000189	0.000771	CcSEcCtD
Tolvaptan—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.00018	0.000736	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000165	0.00226	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000164	0.00225	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000162	0.00223	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000161	0.00221	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	0.000158	0.00217	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.00015	0.00205	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000149	0.00204	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000148	0.00204	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000147	0.00202	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000147	0.00202	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000146	0.00201	CbGpPWpGaD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	0.000144	0.00197	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000137	0.00188	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000136	0.00186	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000135	0.00185	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000134	0.00184	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	0.000128	0.00175	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000124	0.0017	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000123	0.00168	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000116	0.00159	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000116	0.00159	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000115	0.00158	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000115	0.00158	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	0.000113	0.00156	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.84e-05	0.00121	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.78e-05	0.0012	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.71e-05	0.00119	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.64e-05	0.00119	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.58e-05	0.00118	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.52e-05	0.00117	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	8.26e-05	0.00113	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.96e-05	0.00109	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.91e-05	0.00109	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.79e-05	0.00107	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.73e-05	0.00106	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	7.36e-05	0.00101	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	6.26e-05	0.000859	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.6e-05	0.000631	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.58e-05	0.000628	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.57e-05	0.000627	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.55e-05	0.000624	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	4.53e-05	0.000622	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	4.08e-05	0.000559	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	3.86e-05	0.000529	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.74e-05	0.000376	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.7e-05	0.000371	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.68e-05	0.000368	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	1.28e-05	0.000176	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	7.91e-06	0.000109	CbGpPWpGaD
